Organic Active Ingredients TRIZ Cases

CE TOFMS detects specific metabolites to predict therapeutic response, avoiding ineffective treatments and adverse events.

Aceclidine eye drops activate M1 and M3 receptors to increase depth of focus while avoiding distance vision loss.

Conjugating disorazoles with cell-binding molecules concentrates cytotoxicity at tumor sites while reducing systemic toxicity.

A double extrusion process creates a biodegradable polymer matrix that holds dexamethasone within an ocular implant.

Crenezumab targets the C-terminal region of amyloid beta to slow disease progression without causing adverse events like ARIA.

Small molecule IDH1 inhibitors block enzyme activity to disrupt antioxidant defense mechanisms in cancer cells.

Administering intravenous melatonin before percutaneous coronary intervention reduces myocardial infarct size by scavenging free radicals during reperfusion.

Buoyant HPMC and alginate matrices retain bergenin in the stomach, preventing intestinal degradation and enhancing bioavailability by four-fold.

Enzymatically synthesized poly(amine-co-esters) form stable nano-sized polyplexes for nucleic acid delivery.

AICA riboside analogs restore myocardial ATP levels to resolve the trade-off between symptom management and mortality reduction in acute heart failure.

Vinylogous phenethylamine compounds release dopamine and inhibit serotonin uptake while minimizing activity at serotonin-2 receptors to reduce adverse effects.

Optimized adhesive layer composition balances ropinirole concentration with mechanical adhesion properties.

A quinoxaline derivative inhibits PDE9 to modulate cGMP levels and relax urethral smooth muscle.

Sinter powder blends using radiofrequency energy to bond lossy coated particles into tablets with high hardness and rapid disintegration.

Modified pyrone derivatives resist HIV propagation while reducing severe side effects and overcoming drug resistance.

Cepharanthine dihydrochloride salt recrystallizes into polymorphic mixtures to overcome low solubility of free base alkaloids in filovirus treatments.

Novel dioxino-oxazinopyrimidine compounds traverse the blood-brain barrier to inhibit PI3K and suppress tumor growth in malignant gliomas.

Pharmacological Hedgehog pathway inhibition replaces invasive surgery to manage cartilage tumors and prevent malignant progression.

Segmented multilayer coatings with hydrophobic polymer topcoats prevent calcium salt encrustation on ureteral stents through sustained inhibitor release.

Chloroquine triggers Par-4 secretion from normal cells, inducing selective cancer cell apoptosis while sparing healthy tissue.

Pyridylthiazole urea compounds overcome low potency and selectivity by targeting both ROCK1 and ROCK2 isoforms.

A double-layer tablet separates opioid agonists and antagonists to maintain analgesic efficacy while reducing side effects.

Nanoparticle delivery of TCF/LEF inhibitors targets Wnt pathway aberrant expression in cancer stem cells to overcome treatment resistance.

Segmented miRNA formulations target MDM2, A3G, and ADAR1p150 transcripts to reduce leukemia stem cell propagation.

High-concentration leucine and vitamin D3 overcome age-related muscle sensitivity loss, restoring protein synthesis rates.

Structural modifications of RAD51 inhibitors improve metabolic stability and oral exposure while reducing DNA double strand break repair.

Microcapsules encapsulate nanobubbles and drugs to enable precise therapeutic targeting via acoustic cavitation.

Antibodies detect aberrant post-translational modifications on amplified EGFR to minimize normal tissue uptake and enhance anti-tumor activity.

Gel composition replaces painful mechanical nasal packing by applying pressure and promoting coagulation, eliminating infection risks and manual removal.

Solid nicotine salts resolve oil form storage issues by using specific coformers to improve photostability and prevent toxic degradation.

Administering TNFα antagonists blocks inflammatory signaling pathways, preventing post-operative cognitive dysfunction in patients.

Steroidal cationic lipids improve pharmacokinetic properties and targeted delivery precision while reducing toxicity in diverse cell types.

Selective neu1 and neu3 inhibitors block LDL desialylation to reduce arterial inflammation without altering plasma cholesterol levels.

Pyrazolopyrazine derivatives overcome insufficient PTPN11 inhibition by optimizing molecular structure for tumor growth suppression.

Bifunctional compounds recruit Bruton's tyrosine kinase to ubiquitin ligase for targeted proteolytic degradation.

A bi-layer tablet combines immediate release promethazine with controlled release acetaminophen and hydrocodone.

Benzomorphan analogs modulate mu, delta, and kappa opioid receptors to provide analgesia while minimizing constipation and tolerance.

A buccal nicotine spray combines mucolytic agents to reduce mucus viscosity and accelerate drug permeation across the oral mucosa.

C-glycosides inhibit the TGF-β1 signaling pathway to reduce fibroblast conversion, addressing incomplete scar removal by current methods.

A high-temperature endoglucanase method produces defined DP7-DP9 xyloglucan oligosaccharides from polysaccharide sources.

Crosslinked hyaluronic acid gels extend residence time in joints to reduce injection frequency while avoiding the gastric ulcers caused by NSAIDs.

Angiotensin-(1-7) receptor agonists treat cognitive dysfunction by reducing inflammatory cytokines and reactive oxygen species in the central nervous system.

Liposomes encapsulate 2-deamino-2-pyrrolino-daunorubicin to reduce systemic toxicity while maintaining cancer cell killing efficacy.

MPC inhibitors block mitochondrial pyruvate transport to prevent fibrosis progression in primary congenital cardiomyopathies.

Parathyroid hormone combined with a DPP IV inhibitor prolongs SDF-1 upregulation, resolving inefficient stem cell homing in ischemic disorders.

Combines anti-CD79b immunoconjugates with immunomodulatory agents and anti-CD20 antibodies to treat B-cell proliferative disorders.